Researchers at Texas A&M University report the successful regrowth of skeletal and connective tissues, in what they call a “critical step” toward one day enabling major tissue regeneration in humans.

Throughout time, the regenerative capabilities that, in some cases, can even restore entire lost limbs, have been viewed as an almost miraculous ability that only certain animals, such as salamanders, some reptiles, and other creatures, possess.

However, regenerative science is now unlocking the secrets of this capability, meaning that one day, even humans might be able to tap into one of nature’s most mysterious superpowers.

Awakening Humanity’s Dormant Regenerative Superpower

Current state-of-the-art research at the Texas A&M College of Veterinary Medicine and Biomedical Sciences is revealing a remarkable possibility: that regenerative abilities may not be absent in mammals after all—they may simply be dormant.

This remarkable possibility was detailed in a recent study published in Nature Communications, which details research led by Dr. Ken Muneoka with the school’s Department of Veterinary Physiology & Pharmacology (VTPP), who says he has devoted most of his career to unraveling this possibility.

Now, Muneoka and his team report a two-step treatment they developed, which successfully triggered the regeneration of bone, joint structures, ligaments, and other tissues following amputation—a significant advancement toward unlocking more powerful regenerative capabilities in humans.

“Why some animals can regenerate and others, particularly humans, can’t is a big question that has been asked since Aristotle,” Muneoka says.

Fibrolasts to the Fore

In their research, the team worked with cells that drive the healing processes and scar formation after wounds occur, which are known as fibroblasts.

In species like salamanders, similar cells go to work when injury or limb loss occurs, which begin to form into structures biologists call blastemas. These formative materials are the primary drivers behind the regrowth of tissues in such creatures.

However, unlike salamanders, mammalian cells need a bit more encouragement before they will begin to follow such regenerative pathways.

To help with this process, Muneoka and his team developed a new sequential treatment based on a pair of primary growth factors. Applying fibroblast growth factor 2 (FGF2) in an area where a wound had already healed stimulated the formation of blastema-like formations in mammal cells. Then, after several days, a bone morphogenetic protein 2 (BMP2) was applied, which similarly prompted bone cells to begin rebuilding their lost tissues.

“You first shift the cells away from scarring, and then you provide the signals that tell them what to build,” Muneoka said of this two-step process.

While the regenerated structures were not perfect replicas of the original anatomy, what Muneoka and his team achieved is still nothing short of remarkable: the team says they were able to successfully restore all major components that are typically lost when amputation occurs, including bone, tendons, ligaments, and joints.

“The Capacity is Not Absent”

Also of key significance is the fact that the team’s findings suggest that such hidden powers of regeneration might be accessible without the need for introducing external stem cells.

“You don’t have to actually get stem cells and put them back in,” Muneoka said. “They’re already there—you just need to learn how to get them to behave the way you want.”

Dr. Larry Suva, the recent study’s co-author, said the results challenge long-held assumptions about the limits of mammalian healing.

“The cells that we thought to be unprogrammable, in fact are,” Suva said. “The capacity is not absent—it’s just obscured.”

The Future of Regenerative Science

The team’s work is breaking new ground in the promising field of regenerative science, although what they have achieved so far is still in the earliest stages of what they believe may ultimately be possible.

Soon, such approaches may yield applications that could help significantly reduce scarring and may greatly help with tissue repair. Also, since BMP2 has already undergone the approval process for medical uses, and FGF2 is undergoing evaluation in clinical trials, Muneoka, Suva, and the Texas A&M team believe the path toward future medical applications may be more accessible than entirely new therapies.

“Regenerative failure in mammals can be rescued,” Muneoka said.

“Now we have a model to begin figuring out how,” he added.

The team’s recent study, “Digit regeneration in mice is stimulated by sequential treatment with FGF2 and BMP2,” was published in Nature Communications.

Micah Hanks is the Editor-in-Chief and Co-Founder of The Debrief. A longtime reporter on science, defense, and technology with a focus on space and astronomy, he can be reached at micah@thedebrief.org. Follow him on X @MicahHanks, and at micahhanks.com.

Russian cosmonaut Aleksandr Samokutyaev, who served twice as a crew member aboard the International Space Station (ISS), including during the final US space shuttle mission in 2011, has died at the age of 56.

With Samokutyaev's death on Wednesday, he becomes the first former ISS long-duration resident to die in the 26 years that the space station has been a home to 155 other cosmonauts and astronauts as expedition crew members. The cause of his death is unknown.

Portrait of cosmonaut Aleksandr Samokutyaev. Credit: Roscosmos

"The leadership and staff of the Roscosmos State Corporation extend their sincere condolences to the family and loved ones of Aleksandr Mikhailovich," officials with Russia's space agency said in a statement.

Read full article

Comments

© NASA

Russian cosmonaut Aleksandr Samokutyaev, who served twice as a crew member aboard the International Space Station (ISS), including during the final US space shuttle mission in 2011, has died at the age of 56.

With Samokutyaev's death on Wednesday, he becomes the first former ISS long-duration resident to die in the 26 years that the space station has been a home to 155 other cosmonauts and astronauts as expedition crew members. The cause of his death is unknown.

Portrait of cosmonaut Aleksandr Samokutyaev. Credit: Roscosmos

"The leadership and staff of the Roscosmos State Corporation extend their sincere condolences to the family and loved ones of Aleksandr Mikhailovich," officials with Russia's space agency said in a statement.

Read full article

Comments

© NASA

Compound 10 slowed dementia-like decline in mice.

Manger mieux sans rien sacrifier, c'est la promesse tenue du régime méditerranéen. Des études rigoureuses menées sur des dizaines de milliers de personnes le confirment : ce mode alimentaire réduit concrètement le risque de maladies graves. Alors, pourquoi tant de gens ignorent encore ses...

Lucid has registered the design of its upcoming Cosmos with the European Union Intellectual Property Office, giving us the clearest look yet at the sub-$50,000 crossover the automaker is betting its future on.

The filing, published last week, shows the production design of Lucid’s first mass-market EV from every angle, inside and out, months before its expected reveal this summer.

China continued its accelerated launch pace with a series of missions, but long silence followed liftoff of a Kuaizhou-11 solid rocket Wednesday, suggesting potential issues.

The post China conducts 4 launches in 3 days, but silence follows Kuaizhou–11 launch appeared first on SpaceNews.

Space surveillance venture Look Up plans to use Skynopy’s ground station network to help automate its proposed low Earth orbit collision avoidance service, the French startups announced June 17.

The post Look Up and Skynopy partner on automated satellite collision avoidance service appeared first on SpaceNews.

La pollution atmosphérique est un fardeau de plus en plus lourd. La dernière étude de Santé publique France pointe les nombreuses maladies chroniques, respiratoires, cardiovasculaires et métaboliques qu'elle provoque, touchant particulièrement les enfants et les personnes vulnérables. Chaque...

University of California, Irvine Innovates Therapeutic Vaccine Strategy to Combat Recurrent Genital Herpes

In a groundbreaking development that could transform the management of genital herpes, UC Irvine immunologist Lbachir BenMohamed has secured nearly $4 million in funding from the National Institutes of Health to advance a novel therapeutic vaccine approach. This ambitious five-year project aims to tackle recurrent genital herpes caused by herpes simplex virus type 2 (HSV-2), a persistent viral infection that affects over 60 million Americans and more than half a billion individuals globally. Despite extensive research efforts historically, no approved therapeutic vaccine exists to date, leaving millions vulnerable to recurrent outbreaks and transmission.

BenMohamed’s research focuses on a next-generation vaccine strategy termed “Prime/Pull/Keep,” designed to establish a robust, localized immune defense precisely at the mucosal sites where HSV-2 resides and reactivates. Conventional vaccines predominantly elicit circulating antibodies, which are insufficient to control HSV-2’s latent reservoirs in the nerve ganglia and mucosal tissues. This innovative approach instead targets tissue-resident memory T cells (TRM), a specialized subset of immune cells critically positioned at the barrier sites to provide immediate defense against viral reactivation.

The Prime/Pull/Keep methodology encompasses a three-step immunization process: initial priming of protective T cells via vaccination, mobilization of these cells to the infected tissue through chemokine signals (pull), and sustained retention and functional maintenance at the site of infection (keep). Together, these steps ensure a sustained population of antiviral T cells, capable of rapid detection and elimination of reactivated virus, potentially curbing recurrent disease manifestations and viral shedding.

Previous investigations by BenMohamed’s team have demonstrated promising results with mRNA-based therapeutic vaccines in preclinical models. These candidates were effective in reducing clinical signs of recurrent genital herpes and enhancing the recruitment of protective T cells within genital mucosal tissues. Additionally, exploring immune-signaling molecules such as chemokines has validated the feasibility of attracting and retaining TRM populations, thereby improving local immune surveillance and long-term antiviral immunity.

The current NIH-funded project intends to rigorously evaluate the safety profile and immunogenic potential of various Prime/Pull/Keep vaccine candidates in preclinical animal models, examining how augmenting the quantity, quality, and durability of TRM cells correlates with protection from HSV-2 reactivation. This represents a critical translational step toward bridging laboratory research and clinical trials, responding to NIH’s strategic priority to develop novel therapeutic interventions for genital herpes.

BenMohamed articulates the significance of this research succinctly: “People living with recurrent genital herpes have long awaited effective therapeutic vaccines. Our innovative immune-based approach not only amplifies protective T cells but directs and maintains them where the virus hides. This could revolutionize prevention strategies for millions affected worldwide.” The team’s vision is to develop a vaccine capable of reducing recurrent outbreaks and viral transmission, substantially improving quality of life for patients.

HSV-2 represents a formidable pathogen due to its ability to establish lifelong latent infection in sensory neurons, periodically reactivating to cause painful genital lesions and facilitating onward transmission. Existing antiviral therapies focus on suppressing viral replication but do not eliminate reservoirs or prevent recurrence. The targeted boosting of tissue-resident immune memory represents a paradigm shift in immunotherapy, promising durable tissue-specific immunity where it is needed most.

The Prime/Pull/Keep vaccination strategy could also circumvent issues faced by traditional systemic vaccines, which often fail to generate sufficient mucosal immunity or induce long-lasting memory T cell populations within genital tissues. By tailoring antigen delivery and immune modulation, this approach aims to enhance the local microenvironment and foster a self-renewing population of sentinel T cells poised to respond immediately to viral reactivation.

As the project advances through preclinical stages, rigorous assessment of immune correlates of protection will inform optimization of vaccine formulations, dosing schedules, and adjuvant combinations. Understanding the mechanisms underpinning TRM cell maintenance and functionality remains an active area of investigation critical to maximizing therapeutic efficacy and durability.

The successful identification of an optimal Prime/Pull/Keep candidate would pave the way for human clinical trials, marking a historic milestone in the fight against genital herpes. Such a vaccine holds the promise not only to alleviate recurrent symptoms but also to significantly curtail viral shedding, thereby decreasing transmission rates and public health burden.

Beyond genital herpes, the conceptual framework underlying Prime/Pull/Keep may inspire novel immunotherapeutic strategies for other persistent viral infections and chronic diseases where localized immune memory is pivotal. Collaborative efforts among immunologists, virologists, and clinical scientists will be essential to translate these findings into effective interventions.

With UC Irvine’s robust infrastructure, cutting-edge facilities, and interdisciplinary expertise, BenMohamed’s laboratory is well-positioned to spearhead this transformative endeavor. The $3.93 million NIH R01 grant underscores the scientific community’s confidence in this pioneering approach and its potential to redefine therapeutic vaccine development for chronic viral infections.

In conclusion, the UC Irvine-led Prime/Pull/Keep vaccine project represents a beacon of hope for millions plagued by recurrent genital herpes, offering a sophisticated and strategic means to harness the immune system’s power at the precise sites of viral latency and reactivation. As research progresses, the scientific world eagerly anticipates the realization of a durable, tissue-targeted therapeutic vaccine capable of changing the landscape of HSV-2 management and prevention.

Subject of Research: Development of a novel therapeutic vaccine to prevent recurrent genital herpes by targeting tissue-resident memory T cells

Article Title: UC Irvine Advances Prime/Pull/Keep Therapeutic Vaccine Strategy to Combat Recurrent Genital Herpes

News Publication Date: June 16, 2026

Web References:
– University of California, Irvine: www.uci.edu
– UC Irvine News: news.uci.edu
– NIH Media Resources: https://news.uci.edu/media-resources/

Keywords: herpes simplex virus type 2, HSV-2, genital herpes, therapeutic vaccine, tissue-resident memory T cells, Prime/Pull/Keep, immunotherapy, mRNA vaccine, viral latency, NIH funding, recurrent infections, mucosal immunity

Rivian laid off hundreds of workers on Tuesday, or less than 2% of its workforce, just one week after it began deliveries of its all-important R2 SUV.

The electric automaker confirmed the cuts hit its service and customer teams, which include sales and marketing, as it tries to claw its way to a profit it has yet to ever post.

Le 31 mai 2002, c’est l’humiliation pour les Bleus. Presque 25 ans plus tard, ce match contre le Sénégal reste gravé dans les mémoires comme l’un des plus grands upsets du football. Comment une rencontre de Coupe du monde peut-elle ainsi transcender le temps ? La science avance...

China’s Tianwen-2 spacecraft has carried out a series of small propulsive maneuvers following a main burn June 7, setting up an asteroid rendezvous in July.

The post Tianwen-2 makes series of burns on approach to asteroid, according to radio tracking  appeared first on SpaceNews.

The upper stage from a commercial Chinese rocket that launched last week has broken apart in space, spreading debris in a heavily trafficked part of low-Earth orbit home to the International Space Station and a significant portion of SpaceX's Starlink broadband network.

The breakup occurred shortly after the Zhuque-2E rocket reached orbit on June 9 with two satellites providing direct-to-cell communications, perhaps around the time the upper stage was expected to perform a disposal burn. The US Space Force confirmed the breakup event in a post on space-track.org, a website used by the military to distribute orbit data to the public.

"The tracked pieces are being incorporated into routine conjunction assessment to support spaceflight safety," the Space Force wrote in an advisory. "There are currently no threats to human spaceflight. Analysis is ongoing."

Read full article

Comments

© Wang Heng/Xinhua via Getty Images

Japan’s tiny SORA-Q rover showed what happened when SLIM landed upside down.

Scopri come il nuovo bersaglio molecolare GRK2 potrebbe migliorare le terapie per la demenza e l'Alzheimer, aprendo a nuove prospettive di trattamento.

Molti sintomi comuni come stanchezza, sete eccessiva, fame continua e vista sfocata possono essere le prime spia del diabete di tipo 2, una malattia molto frequente ma spesso sottovalutata. Non ignorare questi segnali e fare un controllo del glucosio se persistono.

Il 19 gennaio 2024, il lander giapponese SLIM — soprannominato “Moon Sniper” per la precisione del suo sistema di atterraggio — toccava la superficie lunare diventando il quinto veicolo spaziale nella storia a completare un allunaggio morbido. Quasi subito, però, qualcosa andò storto: i pannelli solari si trovarono orientati nella direzione sbagliata rispetto al sole, […]

The spy law known as Section 702, which authorizes the NSA and FBI's warrantless surveillance, will all but certainly expire on Friday for the first time.

The first batches could reach passenger flights this month.